Journey Medical Corporation
DERMDrugs in Pipeline
6
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Doxycycline
Papulopustular Rosacea
Glycopyrronium Topical Wipes
Hyperhidrosis
DFD-29
Papulopustular Rosacea
Dose 1 of glycopyrrolate, 2.0% QD
Hyperhidrosis
glycopyrrolate, 1.0%
Hyperhidrosis
Glycopyrronium cloth, 2.4%
Palmar Hyperhidrosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Doxycycline | Phase 3 | Papulopustular Rosacea | - | - |
Glycopyrronium Topical Wipes | Phase 3 | Hyperhidrosis | - | - |
DFD-29 | Phase 3 | Papulopustular Rosacea | - | - |
Dose 1 of glycopyrrolate, 2.0% QD | Phase 2 | Hyperhidrosis | - | - |
glycopyrrolate, 1.0% | Phase 2 | Hyperhidrosis | - | - |
Glycopyrronium cloth, 2.4% | Phase 2 | Palmar Hyperhidrosis | - | - |
Hyperhidrosis
3 drugs in this indication
Papulopustular Rosacea
2 drugs in this indication
Palmar Hyperhidrosis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)